Navigation Links
Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference
Date:5/23/2008

EXTON, Pa., May 23 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) is scheduled to present at the FBR 12th Annual Spring Investor Conference at the Grand Hyatt New York Hotel in New York City on Wednesday, May 28, 2008.

Douglas G. Evans, Kensey Nash's COO, will deliver the Company's presentation, beginning at approximately 12:50 p.m. (EDT). To hear the live webcast of the Kensey Nash presentation at the FBR conference, go to http://www.wsw.com/webcast/fbr21/knsy/ and access the conference link. The presentation materials will be available on the company's website (http://www.kenseynash.com) beginning at 12:50 p.m. (EDT) on Wednesday, May 28, 2008.

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily in the sports medicine, spine, and endovascular markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. Kensey Nash has also developed and commercialized a series of innovative endovascular products and recently announced the sale of this product line to Spectranetics, Inc. In conjunction with the sale transaction, the Company will continue to manufacture and develop these products for Spectranetics for a period of time. The Company is known as a pioneer in the field of arterial puncture closure, as the invent
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Corrected Press Release: Kensey Nash to Present at the Bank of America 2008 Health Care Conference
2. Kensey Nash to Present at the Bank of America 2008 Health Care Conference
3. Kensey Nash Reports Third Quarter Record Revenue and Sales
4. Kensey Nash to Participate in the Sidoti Twelfth Annual New York Emerging Growth Institutional Investor Forum Conference
5. Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
6. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
7. Kensey Nash to Present at the 19th Annual Piper Jaffray Health Care Conference
8. Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform
9. Kensey Nash Reports First Quarter Fiscal Year 2008 Results
10. Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares
11. Kensey Nash Announces $25 Million Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...Research(TM), a revolutionary,biometric media res...urement,announced today the appointment of three...earch and development, business strategy and marke..., who deliver a combined 60 years of experience,...nd Vice President of,Strategy; Dr. Ravi Kothuri a...
(Date:11/21/2008)... Texas M. D. Anderson Cancer Center marked the beg...st cancer in Panama through the Partnership for Br... today at an event with Laura Bush, the First Lady...ijos, the First Lady of Panama. , Joining M. D...nt of State and Susan G. Komen for the Cure who ar...
(Date:11/21/2008)...Minnesotans who successfully,quit smoking will re...ion at,the Minnesota Wild game on November 24 at ...ants in The QuitCash Challenge, a new stop-smoking...(R) Services. , The grand prize winner will...l get $1,000 gift cards from Gander Mountain. , ...
(Date:11/21/2008)...entions in computerized brain,training may help p...d fuller,lives, said Jeff Zimman, Chairman of Pos... at the annual Technology Innovators Conference in...nal Center for Technology Innovation to,promote i... Zimman said cognitive training programs can a...
Breaking Medicine News(10 mins):Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research extends to Panama 2Health News:Lucky Quitters to Receive Big Money in Stop-Smoking Contest 2Health News:New Applications for Cognitive Training 2
...The Weizmann Institute of Science’s researchers ha...e apparently well preserved. The Proceedings of th...hed the reports of the scientists. The fossil DNA ...lation dynamics, evolution, diets and diseases, an...
...Professor Timothy Lohman and colleagues from Unive...porosis International// that supplementing post-me...r exercise makes their bone fit and prevents bone ...sity (BMD) which highly reduces the risk of develo...
...A vaccine called RotaTeq for rotavirus has been ap...o vomiting and diarrhea claims the lives of about ...one of the largest clinical trials in history, Mer...ccine on more than 70,000 children that showed it ...
...Breast Tumor Cells may develop due to changes in t...er pregnancy, according to a paper by McDaniel. Th...f The American Journal of Pathology. // The stage...ution dictate drastic changes in the tissues of th...
Other Medicine News:
(Date:11/20/2008)...RSIDE, Calif., Nov. 20 Milk. It do... than originally thought. After years of,research...peptides found in,cow,s milk that stimulate the b... To view the Multimedia News Release, go to:, http..., While developing new cancer therapies, th...
(Date:11/20/2008)...YORK, Nov. 20 Clinical data from a...35th Annual Veith Symposium shows DVT,treatment w... Bacchus,Vascular, Inc. (Santa Clara, CA) success...n about 20 minutes. , This technique, calle...es,blood flow more quickly and safely than curren...
(Date:11/19/2008)...SAND OAKS, Calif., Nov. 19 /PRNewswire-FirstCall/ ...keda Oncology Company, a subsidiary of,Takeda Pha...ounced that,enrollment in the Phase 3 MONET1 tria...ith paclitaxel and carboplatin for the first-line ...(NSCLC) has been temporarily suspended,following ...
(Date:11/19/2008)...RK, Del., Nov. 19 Isogen, a contra... sterile filling, today announced the first,phase...en was founded to,specifically address the proces...ated with the $2 billion highly-niched, low-volume...ing market segment. , Companies can invest ...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Isogen Launches Major New Facility to Address Global Biopharma Demand 2Cardiome Reports First Quarter Results 19236 1Cardiome Reports First Quarter Results 19236 2Cardiome Reports First Quarter Results 19236 3Cardiome Reports First Quarter Results 19236 4Cardiome Reports First Quarter Results 19236 5PharmAthene Reports First Quarter 2008 Financial Results 5367 1PharmAthene Reports First Quarter 2008 Financial Results 5367 2PharmAthene Reports First Quarter 2008 Financial Results 5367 3PharmAthene Reports First Quarter 2008 Financial Results 5367 4PharmAthene Reports First Quarter 2008 Financial Results 5367 5PharmAthene Reports First Quarter 2008 Financial Results 5367 6PharmAthene Reports First Quarter 2008 Financial Results 5367 7Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 1Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 2Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 3Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 4Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 5Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 6Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 7Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 8Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 9Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 10Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 11Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 12Particle Sciences Adds Additional Clean Room Space 5363 1
...0, 2007 - People with a,class of rare genetic diso...ath can be successfully treated with drugs, says a...edicine and Lucile,Packard Children,s Hospital., T...r study that,prompt diagnosis coupled with a rapid...mproves the survival rates of people with,the cond...
...he Treatment of Ischemic,Stroke, GLASGOW, Scotland...ogical Technologies, Inc. (NTI) announced today th...clinical trials of,ancrod and updates on the clini...rinex (ancrod), for the treatment of acute,ischemi...ss in,Glasgow, Scotland in the United Kingdom. Vip...
Other Medicine Technology:Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard,Researcher 2Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard,Researcher 3Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard,Researcher 4Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod) 2Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod) 3Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod) 4
..., real-time thermal cycler used for identifying DN...ing much of the testing process, and making each r...fastest, easiest to use, and most flexible system ... accurate and consistent test results in as little...
...ection System is a high-throughput real-time PCR s...quences. An Automation Accessory combined with 384...lly suited to meet the high-throughput requirement...ns include gene expression quantitation and the de...
Sealing Mat for 384-well, Square Well Plates Available Sterile
Sealing Mat for 384-well PCR Plate, Natural
Medicine Products: